Imiquimod (R 837), an immune response modifier, is a selectivetoll like receptor7 (TLR7)agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts,cancerand COVID-19^[1][2].

In animal models, Imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secrete cytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α^[1].

240.30

Solid

C₁₄H₁₆N₄

99011-02-6

咪喹莫特

Room temperature in continental US; may vary elsewhere.

H₂O : 2.64 mg/mL(10.99 mM;ultrasonic and adjust pH to 2 with HCl)

DMSO : 2 mg/mL(8.32 mM;ultrasonic and warming and heat to 70℃)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。